Clinical trials
Castration Sensitive Prostate Cancer clinical trials
Below are recruiting castration sensitive prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 98 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07216248RecruitingPhase 2
Smart monitoring for men with advanced prostate cancer
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Salt Lake City, UtahAges 18 years+ - NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07190300RecruitingPhase 1/Phase 2
Study of tulmimetostat plus other hormone therapies for metastatic prostate cancer
This study tests two different combinations of drugs for men with prostate cancer that has spread to other parts of the body but still responds to hormone therapy. It compares a new pill (tulmimetostat) combined with standard treatments like darolutamide or abiraterone to see if it can help control the cancer longer.
Birmingham, AlabamaAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Tucson, ArizonaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Goodyear, ArizonaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT06835218Recruiting
Prostate cancer real-world evidence registry
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06738303RecruitingPhase 2
Cabazitaxel with or without carboplatin vs lutetium PSMA for prostate cancer
This trial compares two treatment approaches for advanced prostate cancer that has stopped responding to hormone therapy. One group gets chemotherapy (cabazitaxel with or without carboplatin) and the other gets a targeted radiation therapy (177Lu-PSMA-617). The goal is to see which works better.
Cleveland, OhioAges 19 years+ - NCT06705686RecruitingPhase 1
New drug for advanced prostate cancer
This trial tests an experimental drug called (R)-9b for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can help control the cancer.
Madison, WisconsinAges 18 years+ - NCT06654336RecruitingPhase 2
Targeted therapy with or without hormone therapy for prostate cancer that has spread a little
This trial tests whether targeting the spots where cancer has returned with radiation or surgery, with or without hormone therapy, can help control prostate cancer that has come back in a few places after previous treatment.
Hamilton, OntarioAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+ - NCT06429813Recruiting
Remote exercise program for men with metastatic prostate cancer
This trial tests whether a remotely supervised exercise program (walking and stationary cycling) can help men with metastatic prostate cancer who are starting hormone therapy. Participation involves following an exercise plan at home and may help manage side effects.
Charlottesville, VirginiaAges 18 years+ - NCT06378866RecruitingPhase 2
Radiation with hormone therapy timing for prostate cancer
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
Phoenix, ArizonaAges 18 years+ - NCT06392295RecruitingPhase 2
PSMA-Guided Radiation for Limited Prostate Cancer Return
This trial tests whether targeted radiation to the lymph nodes in the belly can help men whose prostate cancer has returned in just a few spots after prior radiation. You must have had a PSMA PET/CT scan showing the cancer is limited to pelvic or belly lymph nodes.
Miami, FloridaAges 18 years+ - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+
Hear when a new Castration Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for castration sensitive prostate cancer?
- Yes. Clin2 currently lists 98 recruiting castration sensitive prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a castration sensitive prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a castration sensitive prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Hormone Sensitive Prostate Cancer
- Castrate Sensitive Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Castration-Sensitive Prostate Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.